key: cord-1020474-r0hc4eib
authors: Maille, Baptiste; Wilkin, Marie; Millon, Matthieu; Rességuier, Noémie; Franceschi, Frédéric; Koutbi-Franceschi, Linda; Hourdain, Jérôme; Martinez, Elisa; Zabern, Maxime; Gardella, Christophe; Dupont-Tissot, Herve; Singh, Jagmeet P.; Deharo, Jean-Claude; Fiorina, Laurent
title: Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study()
date: 2021-01-29
journal: Int J Cardiol
DOI: 10.1016/j.ijcard.2021.01.002
sha: c26fc6a6495a07a4cd1aa4ec181c6242d1936992
doc_id: 1020474
cord_uid: r0hc4eib

BACKGROUND: QTc interval monitoring, for the prevention of drug-induced arrhythmias is necessary, especially in the context of coronavirus disease 2019 (COVID-19). For the provision of widespread use, surrogates for 12‑lead ECG QTc assessment may be useful. This prospective observational study compared QTc duration assessed by artificial intelligence (AI-QTc) (Cardiologs®, Paris, France) on smartwatch single‑lead electrocardiograms (SW-ECGs) with those measured on 12‑lead ECGs, in patients with early stage COVID-19 treated with a hydroxychloroquine−azithromycin regimen. METHODS: Consecutive patients with COVID-19 who needed hydroxychloroquine−azithromycin therapy, received a smartwatch (Withings Move ECG®, Withings, France). At baseline, day-6 and day-10, a 12‑lead ECG was recorded, and a SW-ECG was transmitted thereafter. Throughout the drug regimen, a SW-ECG was transmitted every morning at rest. Agreement between manual QTc measurement on a 12‑lead ECG and AI-QTc on the corresponding SW-ECG was assessed by the Bland-Altman method. RESULTS: 85 patients (30 men, mean age 38.3 ± 12.2 years) were included in the study. Fair agreement between manual and AI-QTc values was observed, particularly at day-10, where the delay between the 12‑lead ECG and the SW-ECG was the shortest (−2.6 ± 64.7 min): 407 ± 26 ms on the 12‑lead ECG vs 407 ± 22 ms on SW-ECG, bias −1 ms, limits of agreement −46 ms to +45 ms; the difference between the two measures was <50 ms in 98.2% of patients. CONCLUSION: In real-world epidemic conditions, AI-QTc duration measured by SW-ECG is in fair agreement with manual measurements on 12‑lead ECGs. Following further validation, AI-assisted SW-ECGs may be suitable for QTc interval monitoring. REGISTRATION:ClinicalTrial.govNCT04371744.

The current pandemic due to a new coronavirus -severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -has so far affected more than 11 million people and caused in excess of half a million deaths. This healthcare emergency made it necessary to explore pharmacologic interventions to treat or prevent the disease. The use of antiviral drugs is one such intervention, but their efficacy remains debated and strategies for their use are evolutive. [1] In the absence of definitive proof of effectiveness, the safety profile of any treatment is a crucial question. Cardiac toxicity is one of the main concerns because many of the proposed treatments, including lopinavir/ritonavir, chloroquine/hydroxychloroquine (HCQ), azithromycin (AZM), moxyfloxacin and remdesivir, have the potential to cause proarrhythmia, particularly in the setting of severe forms of SARS-CoV2. [2, 3] Monitoring the QT interval and cardiac rhythm are essential for safety considerations regarding the use of these drugs. [3] Some single-lead ECG devices coupled with artificial intelligence (AI) received US Food and Drug Administration clearance for atrial-fibrillation screening, [4] but little is known about the feasibility and diagnostic accuracy of their use for QTc assessment. [5] In light of the shortage of resources and widespread use, and in the context of a highly contagious disease, surrogates for 12-lead electrocardiogram (ECG) assessment may be useful, and direct-to-consumer single-lead ECG technology is promising. If previous study had already shown a good agreement between QTc measured on a Smartwatch ECG (SW-ECG) and a 12 leads ECG, [6] little is known about the use of AI for QTc measurement. The Cardiologs Platform (Cardiologs Technologies™, Paris, France) is a cloudbased platform for ECG interpretation powered by a deep neural network algorithm. This algorithm has already been validated, especially for 12 lead-ECG interpretation in emergency departments, [7] diagnosis of atrial fibrillation, [8] and for Holter analysis. [9] An analog watch with an in-built singlelead ECG (Withings Move ECG™, Withings, France), linked to the Cardiologs™ AI platform, can send self-recorded ECGs direct for AI analysis.

We performed a study to compare QTc assessed using this algorithm on smartwatch single-lead ECGs (AI-QTc) with QTc measured using conventional 12-lead ECGs in patients with early stage coronavirus disease 2019 (COVID-19) treated with the HCQ−AZM regimen.

We identified all consecutive adults (≥18 years) who attended the ambulatory care center of the infectious diseases department of our tertiary referral academic hospital from April 16 to April 24, 2020, for polymerase chain reaction (PCR)-positive SARS-CoV-2 infection. Medical history and current medical status were thoroughly assessed for each patient and the decision to treat with HCQ−AZM was taken by the infectious disease specialist. The study is registered at ClinicalTrials.gov, with the unique identifier NCT04371744. The study was reviewed by the medical research committee of our academic hospital (reference number 2020-52) and approved by the ethical committee (reference number: 2020-030). Signed written informed consent was obtained from all participants.

Once the decision to treat was taken, according to local guidelines, Tisdale Score and recent recommendations [3, 10] a rhythm safety evaluation was systematically performed to assess QTc prolongation risk. Moreover, treatment with HCQ−AZM was not started if the corrected QT interval (QTc; Bazett's formula) was >500 ms, or if the ECG showed patterns suggesting a channelopathy, or if other significant abnormalities (i.e., pathological Q waves, left ventricular hypertrophy, left bundle branch block) were present. The risk−benefit ratio of HCQ−AZM was estimated by the infectious disease specialist and agreed upon with the cardiologist, for a range between 460 and 500 ms of QTc.

In addition, any drug with the potential to prolong the QT interval was discontinued or replaced with another drug for the treatment course. Standard blood chemistry was checked, especially serum creatinine and kalemia in the context of SARS-CoV-2, and the treatment was not started when there was hypokalemia with a serum potassium <3 mEq/L, and was discontinued at day 1 if the serum potassium between 3 and 3.5 mEq/l was not normalized.

ECG recording:

All patients who were prescribed HCQ−AZM treatment and had no criteria for overnight stay were considered for inclusion in the study if they had a smartphone and were able and willing to perform repeated SW-ECGs. They received a smartwatch (Withings Move ECG™) and were instructed on how to use it. A 12-lead ECG was then recorded at rest (baseline), with a paper speed of 50 mm/s and an amplitude calibration of 10 mm/mV (MAC® 3500 or MAC® 1600 recorder; GE Healthcare Europe, Freiburg, Germany). As soon as technically possible, an ECG recording was taken with the smartwatch. Patients were then allowed to go home. The drug regimen was as follows: hydroxychloroquine (Plaquenil®; Sanofi Aventis, Paris, France), 200 mg three times per day for 10 days, plus azithromycin (Zithromax®; Pfizer Holding, Paris, France), 500 mg once a day on the first day, then 250 mg once a day for 4 days.

The patients were instructed to transmit a SW-ECG every morning at rest and at any time in case of unusual symptoms, including palpitations or dizziness, until the end of the treatment. As per local guidelines, patients were requested to attend a follow-up visit at the ambulatory care center of the infectious disease department for clinical assessment and a 12-lead ECG on the sixth day (day-6, recommended) and on the last day of therapy (day-10, mandatory). They transmitted a SW-ECG as soon as technically possible after the 12-lead ECG recording at day-6 and day-10 ( Figure 1 ).

Manual Interpretation J o u r n a l P r e -p r o o f Journal Pre-proof On the standard 12-lead ECG recordings obtained at baseline, day-6 and day-10, the QT interval was measured, as recommended [11] in the tangent method, in lead II or V5, and corrected using Bazett's formula. In addition, QTc was assessed on lead I using the same method. Additional measurement included heart rate, and any cases of arrhythmia were recorded. PR interval and QRS duration were The convolutional neural network consists of a U-net architecture [12] with 11 convolutional layers and 6 residual blocks. The network takes as input the ECG signal and outputs the onsets and offsets of all detected P, QRS and T waves. The network was trained on 6315 resting ECGs and Holter recordings, with the onsets and offsets of P, QRS and T waves annotated by experts in electrophysiology following standard procedures. No SW-ECG was used during training of the neural network. The SW-ECGs were single lead ECGs lasting 30 s and sampled at 300 Hz, a sampling rate which is similar to the recordings used for training (100 to 500 Hz). The network was implemented in Keras, with a backend in Tensorflow (Google, Mountainview, California), and trained using stochastic gradient descent. Early stopping and dropout regularization were used to avoid overfitting. [13] In order to ensure that the network performs accurately for multiple and single lead ECGs, leads were sometimes randomly subsampled during training. The performance of the AI-QT measurement was evaluated on the Common Standards for Quantitative Electrocardiography database. [14] The bias of the QT measurement was -13.7 ms, with a standard deviation of 7.3 ms.

The primary outcome was the agreement between the standard 12-lead QTc interval measured manually in lead II or V5 at baseline and day-10, and the AI-QTc measured on the corresponding SW-ECG.

Secondary outcomes included the agreement between the standard 12-lead QTc measured manually in lead II or V5 at the day-6 visit and the AI-QTc on the corresponding SW-ECG; agreement between the 12-lead QTc measured manually in lead I at baseline, day-6 and day-10 and the AI-QTc on the corresponding SW-ECG; agreement between the QTc measured by the cardiologist on the daily SW-ECG and the AI-QTc on the same SW-ECG, at day-10; and a description of QTc behavior during HCQ-J o u r n a l P r e -p r o o f AZM therapy and of arrhythmia occurrence as assessed on daily SW-ECGs or on-demand SW-ECGs (i.e. in case of symptoms).

Quantitative variables are presented as means ± standard deviations (SD) and categorical variables as numbers (percentages). Agreement between QTc measurements (between manual QTc measurement on the 12-lead ECGs and AI-QTc, between QTc measured manually on the same SW-ECG and AI-QTc) was assessed using the Bland-Altman method. The mean of the difference (bias) in QTc interval between the 2 methods was calculated, as well as the lower and upper limits of agreement. Agreement between measures was also numerically assessed by estimating the agreement intraclass correlation coefficient (ICC), with its 95% confidence interval (CI). Daily smartwatch QTc were compared with baseline smartwatch QTc by means of a paired t-test. The Benjamini−Hochberg procedure was used for controlling the false positive rate in multiple comparisons.

All analyses were performed using R software, version 3.6.3. All tests were 2-sided, and P<0.05 was considered statistically significant. Table 1 . In 3 patients (3.9%), serum potassium was between J o u r n a l P r e -p r o o f Journal Pre-proof 3 and 3.5 mmol/L at inclusion; they received potassium supplementation, achieving normo-kalemia after 1 day, and could continue the treatment. Ten patients (13.1%) were taking concomitant QTprolonging drugs (antihistamine drugs) and 2(2.6%) were taking beta-blockers. These treatments were all discontinued on the decision of the infectious disease specialist as they were not considered essential. No patient had a significant ECG abnormality or underlying severe cardiac disease. Among patients who received the drug regimen and were followed with daily SW-ECGs, median Tisdale score was 7 (6-7). Respectively 26(34.2%), 50(65.8%) and 0(0%) presented a low, moderate and high risk of prolonging QTc.

Mean follow-up was 10.8±1.2 days. One patient had to be admitted to the conventional ward because of a deterioration in his respiratory function at day 5 of treatment and stayed in hospital for 5 days. No more SW-ECGs were recorded after he was admitted to the hospital, but clinical follow-up and a 12-lead ECG at day 10 were still available. By their own decision, 17(22.4%) patients did not attend the optional day-6 visit and 2(2.6%) did not attend day-10 visit. They were contacted at day-10, and it was confirmed that they did not experience palpitations or syncope. One patient declared a minor cutaneous allergic reaction with pruritus related to the watch strap, which did not prevent the patient from sending daily recordings. With this exception, no patient declared any difficulty in the wearing the smartwatch.

Owing to technical issues in communication between their smartwatch and smartphone, 5/71(6.6%), 5/53(8.6%) and 7/66(9.6%) patients were unable to record a SW-ECG after the 12 lead-ECG during the visit at baseline, day-6, and day-10, respectively. A mean of 9.5±2.1 SW-ECGs were recorded per patient. Fifty (65.8%) patients performed at least 10 SW-ECGs during the 11 days of follow-up, while 6(7.9%) performed fewer than 6 SW-ECGs. No patient reported palpitations, dizziness, or syncope.

The number of patients in whom 12-lead and SW-ECGs could be compared at each visit is detailed in Table 2 .

The delay between completion of the standard 12-lead ECG and the SW-ECG was 55.7±141.3 min at baseline, 38.2±129.1 min at day-6, and −2.6±64.7 min at day-10. Table 2 shows the agreement between the manually measured QTc on the 12-lead ECG, the manually measured QTc on lead I of the same tracing, and AI-QTc from the corresponding SW-ECG. When the delay between completion of the 12-lead ECG and the SW-ECG was the shortest, at day-10, the Bland-Altmann diagram (Table 2, Figure 2B ) showed the best agreement. Similar results were obtained at day-6 ( One patient had a AI-QTc >500 ms (i.e. 502 ms) on the second day of treatment and was therefore admitted to the day-hospital. The 12-lead ECG showed a prominent U wave in lead I, along with a low T-wave amplitude. In this patient, baseline 12-lead QTc interval was 457 ms and no AI-QTc was available at baseline because of pairing issues between the smartphone and the smartwatch. The 12lead QTc measured in hospital on day 2 was 471 ms, thus the drug regimen was continued at home.

No QTc value >500 ms was observed on either the subsequent daily AI-QTc or 12-lead ECGs during follow-up.

In the general population, a slight but significant PR prolongation was observed at day-10 (154±25 ms at baseline to 161±23 ms at day-10; P<0.001). There was no significant QRS prolongation from baseline (83±19 ms) to day-10 (86±17 ms) (P=0.3).

Four patients (5.2%) presented with asymptomatic premature ventricular contractions (PVC) on their daily SW-ECGs. All of them had also had such PVC's on their 12 lead-ECG at baseline. No other arrhythmia was identified during follow-up.

We observed a fair agreement between the QTc interval duration measured manually on a standard 12-lead ECG and assessed by AI on single-lead smartwatch recordings. This agreement was observed on different sets of tracings obtained at various points throughout the study, provided they were recorded at similar times. In this young population of patients with early stage COVID-19 and mild-tomoderate symptoms, no significant QTc prolongation was observed on daily AI-QTc and no lifethreatening arrhythmias were reported. Whereas one study has already demonstrated the power of a deep learning algorithm for diagnosis of arrhythmia, [4] the current is the first to evaluate a deep neural network with SW-ECGs for QT monitoring.

A few studies [15, 16] and recent recommendations [17] have highlighted the major interest of using connected devices in the context of the potential use of QT-prolonging drugs in COVID-19 therapy.

Previous studies described the utility of various connected ECG recording devices, such as smartphones, [15, 18] wearable remote monitoring systems, [19] smartwatches, [6] and mobile cardiac telemetry [16] for QTc monitoring. Some have also described the use of automatic measurement of the QTc using different automatic algorithms, but not neural network-based AI, embedded on recording devices or proprietary. Our study is the first to confirm the feasibility and accuracy of a neural network-based AI-QTc determination, using ECG independently gathered from direct-to-consumer SW-ECG, in real-life conditions of COVID-19 therapy.

Agreement between 12-lead ECG and a SW-ECG QTc measurements have been shown to be dependent on factors such as ECG tracing quality and T-wave amplitude. [6] Different strategies of improving agreement accuracy have been described. Strik et al. used "T-wave mapping" screening to identify the best smartwatch position and withdrew from their study patients in whom the different smartwatch positions did not allow for adequate measurement. [6] Other investigators excluded patients with poor quality of reference ECG tracing. In our real life study, no patient was excluded based on the shape or quality of the SW-ECG, and only standard recording (i.e. with the watch worn on the wrist) was performed. Moreover, no SW-ECG was used during training of our neural network.

Due to the COVID 19 pandemic emergency situation, there was not enough time to apply such a strategy of specific neural network training. Despite this imperfect emergency protocol, we found a fair agreement with manual-QTc, comparable to that reported in the literature. [6, [15] [16] [17] 20] . We expect the use of a specific AI trained with SW-ECGs would demonstrate more accurate agreement.

There are numerous sources of potential discrepancy in QTc interval assessment, ranging from interobserver variability and precision of the measurement technology to intrinsic variability of the QTc itself. The discrepancy between manual QTc measurements, even when performed by experts, is wide, ranging from 34 to 80 ms. [20] In addition, QT interval is a highly dynamic parameter, showing J o u r n a l P r e -p r o o f well-known circadian variations. Apart from heart rate itself, it is highly sensitive to autonomic nervous system influences [21] and to many pathologic conditions such as ischemia. [22] Even if we did our best to perform smartwatch and 12-lead ECG recordings as close in time as possible, a significant delay was observed in some cases for various reasons that may reflect real life. In spite of a potential multifactorial QTc variability in measurements, we found acceptable agreement.

As the SW-ECG records a lead equivalent to lead I of the ECG, we were expecting stronger agreement between AI and manual QTc when the measure was performed in lead I. AI-QTc was consistently overestimated compared with lead 1 QTc, but a similar limit of agreement with 12-lead QTc was observed. There is no clear explanation, but we assume that it might be due to the fact that lead I is not optimal for QT measurement for various reasons, including the shape or amplitude of the T wave in lead I, and the QT dispersion on a 12-lead ECG. [23, 24] We believe that AI may compensate for some of these issues by computing a median over all beats, removing the extreme and aberrant values, whereas manual measurement only relies on a few beats.

While HCQ effectiveness in COVID-19 is criticized, [25] its use in connective tissue disease is wide [26] and antiviral strategies in COVID-19 still unresolved. Moreover this study was not designed to test the effectiveness of HCQ−AZM in COVID-19 but rather to examine cardiac safety profile of such medication. The use of HCQ−AZM in patients with early stage COVID-19 with mild-to-moderate symptoms in an ambulatory care center, was not related with significant prolongation of the QTc interval during the drug regimen or significant arrhythmia occurrence. However, HCQ may lead to QT prolongation. HCQ is a derivative of chloroquine and has similarities to quinine, which is a class Ia antiarrhythmic drug that acts as a sodium channel blocker, responsible for prolonging the duration of the action potential, and may therefore prolong the QT interval. However, this effect is expected to be modest. [27] AZM has low affinity for the hERG channel, [28] and is therefore considered to have a low risk of QT prolongation. However, combining both drugs, particularly when taking into account the increased risk of electrolyte disorders in patients with severe COVID-19, may result in a J o u r n a l P r e -p r o o f proarrhythmic effect. Recent publications [29, 30] evaluating HCQ−AZM treatment in hospitalized patients with COVID-19, with a mean age greater than 60 years, and including severe and critically ill patients with COVID-19, have shown important QTc lengthening in some patients. However, other evaluating lower risk patients, [31] similarly to our study, showed only modest QTc prolongation. This highlighted the necessity of an initial QTc prolongation risk evaluation and a close QTc monitoring, for patients under prolonging QTc drugs. Thus a home-monitoring ECG is of greatest interest, in the context of the required social distancing, because of the COVID-19 pandemic.

One of the limitations of our study is the very low number of critical QTc prolongations. This is likely due to our cardiac-rhythm safety criteria for HCQ−AZM therapy. Although the accuracy for monitoring pathologic QTc prolongation remains uncertain, the agreement we found makes it a promising strategy.

Our study also highlights some limitations of SW-ECG follow-up, including willingness and capacity to participate, technical skills, and adequate internet coverage. Twelve patients were not included because of an anticipated poor adherence to the study protocol (either related to patient choice or understanding), and 7 additional patients were withdrawn for technical issues after inclusion. A small number of patients occasionally did not transmit daily SW-ECG data. Finally, as previously mentioned, owing to poor internet coverage in the daycare facility, simultaneous 12-lead ECGs and SW-ECGs were unpredictively not feasible. Despite these issues, participation in the study was good, Solid blue and dashed red lines represent the bias limit of agreement in the QTc interval between the 2 methods. 12-lead QTc denotes QTc interval measured on a 12-lead ECG; AI artificial intelligence;

and ECG, electrocardiogram. J o u r n a l P r e -p r o o f 

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol

Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment

Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network

QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation

Validating QT-Interval Measurement Using the Apple Watch ECG to Enable Remote Monitoring During the COVID-19 Pandemic

A deep neural network learning algorithm outperforms a conventional algorithm for emergency department electrocardiogram interpretation

A deep neural network for 12-lead electrocardiogram interpretation outperforms a conventional algorithm, and its physician overread, in the diagnosis of atrial fibrillation

Abstract 9825: Artificial Intelligence Based Platform Enables Faster Ambulatory Electrocardiogram Analysis With Equivalent Clinical Accuracy Compared to Traditional Solution

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients

Accurate electrocardiographic assessment of the QT interval: teach the tangent

Dropout: a simple way to prevent neural networks from overfitting

Dropout: A Simple Way to Prevent Neural Networks from Overfitting

CSE database: extended annotations and new recommendations for ECG software testing

Multilead QT Screening Is Necessary for QT Measurement: Implications for Management of Patients in the COVID-19 Era

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic

Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide

A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome

Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one

Role of sympathovagal interaction in diurnal variation of QT interval

QT dispersion, daily variations, QT interval adaptation and late potentials as risk markers for ventricular tachycardia

QT interval variability in body surface ECG: measurement, physiological basis, and clinical value: position statement and consensus guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group on Cardiac Cellular Electrophysiology

Importance of lead selection in QT interval measurement

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force

Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology

Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin

Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings

Two automatic QT algorithms compared with manual measurement in identification of long QT syndrome

Comparison of automatic QT measurement techniques in the normal 12 lead electrocardiogram

limits of agreement; and SW, smartwatch. Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac

Conceptualization, Methodology, Resources, Writing -Original Draft Marie Wilkin: Conceptualization, Methodology, Resources, Writing -Original Draft Matthieu Millon: Resources Noémie Rességuier: Methodology, Frédéric Franceschi: Resources Linda Koutbi-Franceschi: Resources Jérôme Hourdain: Resources Elisa Martinez: Resources Maxime Zabern: Resources Christophe Gardella: Conceptualization, Methodology, Software, Writing -Original Draft Herve Dupont-Tissot: Resources Jagmeet P. Singhl: Conceptualization

Writing -Original Draft, Supervision Laurent Fiorina: Conceptualization, Methodology, Writing -Original Draft